AVE1625

DRUG2 trials

Sponsors

Sanofi

Conditions

Alzheimer DiseaseSchizophrenia

Phase 1

Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

CompletedNCT00380302

SanofiAlzheimer Disease

Start: 2006-09-30End: 2007-07-31Updated: 2008-12-19

Phase 2

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

TerminatedNCT00439634

SanofiSchizophrenia

Start: 2007-02-28End: 2009-09-30Updated: 2016-05-18